DR. LAL PATHLABS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,519 INR | -0.13% |
|
+7.23% | -2.33% |
| May. 14 | Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 | MT |
| May. 13 | Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 22.27B 267M | Sales 2025 * | 24.98B 299M | Capitalization | 209B 2.51B |
|---|---|---|---|---|---|
| Net income 2024 | 3.58B 42.85M | Net income 2025 * | 4.18B 50.03M | EV / Sales 2024 | 8.44 x |
| Net cash position 2024 * | 7.68B 92.01M | Net cash position 2025 * | 9.78B 117M | EV / Sales 2025 * | 7.99 x |
| P/E ratio 2024 |
52.6
x | P/E ratio 2025 * |
50.5
x | Employees | 4,048 |
| Yield 2024 * |
0.67% | Yield 2025 * |
0.87% | Free-Float | 43.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Lal PathLabs Limited
More recommendations
| 1 day | -0.17% | ||
| 1 week | +7.23% | ||
| Current month | +6.12% | ||
| 1 month | +12.16% | ||
| 3 months | +0.67% | ||
| 6 months | -6.71% | ||
| Current year | -2.33% |
1 week
2 417.00
2 540.00
1 month
2 165.802 540.00
Current year
1 943.702 662.00
1 year
1 916.052 767.10
3 years
1 762.054 245.50
5 years
1 005.554 245.50
10 years
696.504 245.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ved Prakash Goel
DFI | Director of Finance/CFO | - | 05-12-31 |
Arvind Lal
CHM | Chairman | 74 | 95-02-13 |
Munender Soperna
CTO | Chief Tech/Sci/R&D Officer | - | 07-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 23-07-26 | |
| Director/Board Member | 77 | 15-08-20 | |
Arvind Lal
CHM | Chairman | 74 | 95-02-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 6 M€ | +6.07% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 112 M€ | +5.51% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2,519 | -0.13% | 48 614 |
| 24-05-16 | 2,522 | +1.95% | 346,454 |
| 24-05-15 | 2,474 | -0.72% | 186,576 |
| 24-05-14 | 2,492 | -0.11% | 341,588 |
| 24-05-13 | 2,494 | +6.24% | 1,871,379 |
Delayed Quote NSE India S.E., May 17, 2024 at 12:47 am EDT
More quotes
Dr. Lal PathLabs Limited is an India-based company that is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Companyâs subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.
Calendar
2024-06-28
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
2,522
INR
Average target price
2,489
INR
Spread / Average Target
-1.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.33% | 2.51B | |
| -16.02% | 8.67B | |
| +65.60% | 4.25B | |
| -9.46% | 2.47B | |
| -44.11% | 2.25B | |
| -7.42% | 1.91B | |
| -18.68% | 1.56B | |
| -41.75% | 1.19B | |
| +11.31% | 1.15B | |
| +14.50% | 964M |
- Stock Market
- Equities
- LALPATHLAB Stock
